Table 5: Overview of KD-Induced Microbiota Changes in Non-cancer Studies

Study Citation	Purpose	Design	N	Diet	Length	KD-induced Microbiota Compositional Changes	Additional Notes	Sequencing Type
(34)	To understand how KDs affect the gut microbiome and the downstream consequences for host metabolism and immunity	Inpatient crossover study in overweight or class I obese non-diabetic men	n=17	BD: 35%:15%:50% [fat:protein:CHO], KD: 80%:15%5%	8 weeks (4 weeks BD, 4 weeks KD)	Firmicutes, ↓ Actinobacteria Genera: 19 genera changed	SCFA levels or bacterial load. Significant overall separation in fecal metabolite profiles	16S, metaG
(35)	To examine how the fecal microbiome is affected by KD in children with epilepsy	Children with therapy-resistant inoperable epilepsy or a diagnosis of a neurometabolic disorder served as the experimental group. One parent per trial served as a "control" and followed normal intake of a standard western diet.		KD: 4:1 [fat:protein+CHO] in 7 children, 3.5:1 [fat:protein+CHO] in 2 children, 3:1 [fat:protein+CHO] in 3 children		Proteobacteria (notably Eschericha coli) ↓ Firmicutes (notably Eubacterium rectale), ↓	change in alpha diversity on KD. Beta diversity and PCA revealed KD patient samples became more functionally and taxonomically distinct after 3 months.	metaG
(38)	To investigate if MMKD can beneficially alter the gut microbiome and SCFA production and whether the changes are associated with improvements in Alzheimer's disease biomarkers	Randomized, double-blind, crossover study in older adults at risk for Alzheimer's Disease		MMKD: 60-65%:30-35%:<10%, AAHD: 15-20%, 20-30%,55-65%	weeks	Phyla: No signifcant changes in the dominant phyla (Firmicutes, Bacteroidetes, Proteobacteria), ↑ Tenericutes (slight), Genera/Family: ↓ Bifidobacterium (signifcant reduce), ↑ Akkermansia, ↑ Slackia, ↑ Enterobacteriaceae, ↓ Lachnobacterium	Changes in fecal levels of organic acids: ↑ Butyrate, ↓ Acetate	16S
(37)	affects metabolic	Single-arm study in women aged 20-65 years with a BMI of > 25 kg/m2		KD: >70% of energy from fats, 1 g/kg protein, <20 g CHO	6 weeks	$(1.2\% \rightarrow 1.4\%)$ , ↑ Tenericutes $(0.2\% \rightarrow 0.3\%)$ , ↓ Bacteroidetes $(25.7\% \rightarrow 4.2\%)$ , ↓	SCFA production (acetate, propionate, butyrate) decreased significantly, Alpha diversity (Chao1, Shannon, inverse Simpson) showed a trend toward reduction, but was not statistically significant,	16S

						Blautia (p = 0.031), ↑ Akkermansia, ↑ Lactobacillus, ↓ Prevotella (p = 0.025), ↓ Bifidobacterium, ↓ Coprococcus	Beta-diversity decreased significantly.	
(36)	To examine the effects of KD therapy on intestinal microbiota composition in children with refractory epilepsy and bacterial biomarkers	children with monthly seizures and therapy with ≥ 2 antiepileptic	n=20	KD: 4:1 [fat:protein+CHO]	6 months	Phyla: ↑ Bacteroidetes, ↓ Firmicutes, ↓ Actinobacteria, Proteobacteria was unchanged Genera/Family/Order: ↑ Bacteroides, ↑ Bacteroidia, ↓ Clostridiales, ↓ Clostridia, ↓ Ruminococcaceae, ↓ Faecalibacterium	Non-significant reduction in alpha diversity. Significant difference in beta-diversity (ANOSIM R=0.447, p=0.001). ↑ uric acid, ↑ free fatty acids, ↑ cholesterol, ↑ triglycerides, ↑ LDL, ↓ HDL, ↓ total bilirubin	16S

KD=ketogenic diet MMKD = modified mediterranean ketogenic diet SCFA = short-chain fatty acid PCA = principal component

analysis

FDR = false discovery rate BMI = body mass index